

BEST AVAILABLE COPY



Europäisches Patentamt
European Patent Office
Office européen des brevets

⑪ Publication number:

0 394 538
A1

⑫

EUROPEAN PATENT APPLICATION

⑬ Application number: 89107780.2

⑮ Int. Cl. 5: C12N 1/19, C12P 21/02,
C12N 15/81, // (C12N1/19,
C12R1:645)

⑯ Date of filing: 28.04.89

⑭ Date of publication of application:
31.10.90 Bulletin 90/44

⑰ Inventor: Hollenberg, Cornelius P., Prof. Dr.
Chopin-Str. 7
D-4000 Düsseldorf(DE)
Inventor: Strasser, Alexander, Dr.
Ringelsweide 16
D-4000 Düsseldorf(DE)

⑯ Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE
⑰ Applicant: Rhein Biotech Gesellschaft für
biotechnologische Prozesse und Produkte
mbH
Erkrather Strasse 230
D-4000 Düsseldorf 1(DE)


⑰ Representative: Patentanwälte Grünecker,
Kinkeldey, Stockmair & Partner
Maximilianstrasse 58
D-8000 München 22(DE)

⑲ A yeast cell of the genus schwanniomyces.

⑳ The present invention relates to a yeast cell of the genus Schwanniomyces wherein said yeast cell contains at least one expression cassette comprising:

- a first DNA sequence serving as a regulon,
- optionally a second DNA sequence coding for a signal peptide,
- a third DNA sequence coding for a foreign protein, and
- optionally a fourth DNA sequence serving as a terminator.

In a preferred embodiment of the invention, the first, second and/or fourth DNA sequences are derived from genes coding for amylolytic enzymes of yeast cells of the genus Schwanniomyces. The use of these functional sequences in an expression cassette provides efficient expression of foreign genes in yeast cells according to the present invention and, furthermore, provides a system for efficient secretion of the expression product into the medium.



EP 0 394 538 A1

The present invention relates to yeast cells of the genus Schwanniomyces and a process for the production of polypeptides.

For expression of eukaryotic proteins of biotechnological relevance there exists a variety of host systems, which are selected in compliance with the specific requirements. The most frequently used host organism is Escherichia coli, being the best known representative of prokaryotic host organisms; Saccharomyces cerevisiae and animal tissue cultures are used as eukaryotic host cells. For certain purposes, e.g. where expression of a glycoprotein is desired, expression in E.coli or other prokaryotic organisms is not appropriate, since same lack any glycosylation capability. On the other hand, the mass production of protein in tissue cultures still is cumbersome and expensive; therefore, the organism of choice in many instances is yeast of the well characterized genus Saccharomyces. S. cerevisiae is able to secrete efficiently small proteins, e.g. polypeptides like MG1 (Kurjan and Herskowitz, 1982), β -endorphin or α -interferon (Bitter et al., 1984), however proteins of higher molecular weight are captured in the periplasmic space (Emr et al., 1981) or the cytoplasma, thus causing decreased growth rates or even death of the cell. Therefore it is an object of the present invention to provide an improved eukaryotic expression system, which is optionally capable of secreting proteins encoded by a foreign DNA into the culture medium.

This object has been solved by a yeast cell of the genus Schwanniomyces, wherein said yeast cell

15 contains at least one expression cassette comprising :

a) a first DNA sequence serving as a regulon,
b) optionally a second DNA sequence coding for a signal peptide
c) a third DNA sequence coding for a foreign protein, and
d) optionally a fourth DNA sequence serving as a terminator.

20 The invention, which comprises further subjects, is now described in a more detailed manner by the following description, examples and figures.

BRIEF DESCRIPTION OF THE FIGURES

25 **Fig.1**
A: Restriction map of the AMY1 gene encoding α -amylase and its 5' and 3' noncoding region
B: Nucleotide sequence of the AMY1 gene and its flanking region. In the 5' region the transcription initiation site is indicated by a dashed line above the sequence. Within the structural gene the presumptive signal peptidase cleavage sites are indicated by star-symbols. The two potential glycosylation sites, the cystein residues presumably forming four disulfide bonds (concluded by homology to the A. oryzae enzyme) are underlined. Within the 3' end region the transcription termination signal TAG...TATGT...TTT is indicated by a solid line.

30 **Fig.2**
A: Restriction map of the GAM1 gene encoding glucoamylase and its 5' and 3' noncoding region
B: Nucleotide sequence of the GAM1 gene and its flanking region. In the 5' region the transcription initiation site is indicated by a dashed line. Within the structural gene the presumptive signal peptides cleavage sites are indicated by star-symbols.

35 **Fig.3**
40 M13 Xhol. The EcoRI-Scal fragment, containing a 1.8 kb promoter fragment and approx. 0.4 kb structural gene fragment of α -amylase gene, was subcloned into M13mp8 previously digested with EcoRI and SmaI. By site directed mutagenesis a XhoI-site was inserted just in front of the ATG codon:

** *

45 5' ... TAAAATAAAAGCTCGAGATGAGATTT...3'.

Positions where bases have been exchanged by site directed mutagenesis, are indicated by asterisks.

Fig.4
50 pMaGAM-B/S. The BgIII fragment containing the glucoamylase gene and its 5' and 3' flanking region was subcloned into the BamHI site of vector pMAC5-8 (Kramer et al., 1984). By site directed mutagenesis using the gapped duplex DNA methode (Kramer et al., 1984) a BamHI site and a SalI site were inserted just in front of the translation initiation codon ATG:

* ***** *

5'... CTCATGACTGTGTCGACGGATCCAAGATGATTTT...3'.

5 Positions affected by the site specific mutagenesis are indicated by asterisks.

Fig. 5

YRp7 α GAM. The GAM gene was isolated from pMaGAM-B/S as a Sall fragment and ligated into the XhoI site of M13 α Xho (Fig.3). The BgIII fragment harbouring the α -amylase promoter GAM gene fusion was ligated into the single BamHI site of the S. cerevisiae vector YRp7 resulting in plasmid YRp7 α GAM.

10 Fig.6

Construction of S. occidentalis vectors for expression of foreign genes using the promoter and the signal sequence of the glucoamylase gene.

15 a: Insertion of the 4.0 kb EcoRI-PvuII fragment from pBRSwARSGAM, containing the complete GAM promoter and the first 208 bp of the GAM encoding sequence into pRR322, cleaved with EcoRI/PvuII, resulting in vector pBRGAM.

b: Insertion of the 3.4 kb PvuII fragment from plasmid pCT603, containing the structural gene coding for cellulase from base pair position +112, into the PvuII site of plasmid pBRGAM, resulting in vector pBRGC1.

20 c: Insertion of the 5.5 kb BgIII-PstI fragment from plasmid pBRGC1 into BamHI/PstI cut pCJD5-1. The resulting plasmid, pMPGC1-1 contains 321 bp of the GAM 5' non coding region and the first 208 bp of the GAM coding region fused to position +112 of the celD gene.

d: Insertion of the 6.5 kb BamHI-PstI fragment from plasmid pBRGC1 into BamHI/PstI cut pCJD5-1. The resulting plasmid, pMPGC1-2 contains 1.3 kb of the GAM 5' non coding region and the first 208 bp of the GAM coding region fused to position +112 of the celD.

25 Fig. 7

Promoter studies using the qualitative endoglucanase D activity assay (congo red staining) with different transformants:

NGA58: pMPAGC, NGA58: pMPPGC, NGA58: pMPGC1-1, NGA58: pMPGC1-2

30 a: Growth on 2% maltose
b: Growth on 4% glucose

Fig.8

Construction of a S. occidentalis vector for expression of foreign genes under control of the ADH1 promoter.

35 a: Insertion of the 1.45 kb BamHI-Sall ADH1 promoter fragment of plasmid pFM2-1 into pCJD5-1, previously cut with BamHI/Sall resulting in plasmid pMPADH1.

b: Insertion of the 3.2 kb Sall fragment of pJDcg-15 into the Sall site of pMPADH1, resulting in pMPAG.

c: Exchange of the GAM promoter in plasmid pMPGC1-2 (Fig. 6d) for the ADH1 promoter from plasmid pMPAG by in vivo recombination, resulting in plasmid pMPAGC.

40 Fig. 9

Construction of a S. occidentalis vector for the expression of foreign genes under control of the PDC promoter.

a: Insertion of the 6.0 kb SphI-Aval fragment from plasmid pJDcg-15, containing the PDC promoter fused to the GAM gene into YRpJD2 previously cleaved with SphI-Aval, resulting in plasmid pMPPG.

45 b: Exchange of the GAM promoter in plasmid pMPGC1-2 (Fig. 6d) for the PDC promoter from plasmid pMPPG by in vivo recombination, resulting in plasmid pMPPGC.

Fig. 10

Construction of an autonomous replicating vector (containing SwARS2) for transformation of S. occidentalis. The 3.2 kb TRP5 BamHI fragment from plasmid YRpJD2 was ligated with the 5.5 kb BamHI-BgIII fragment of plasmid pBRSwARSGAM (Fig. 6a), resulting in pMPTS2-A and pMPTS2-B.

50 ABBREVIATIONS USED THROUGHOUT THE APPLICATION

55 **Restriction endonucleases :**

Aa-AatII
A - Asp718

B - BamHI
 Bg - BgIII
 C - CiaI
 E - EcoRI

5 EV - EcoRV

H - HindIII

P - PvuII

Ps - PstI

S - SalI

10 Sc - ScaI

Sm - SmaI

Sp - SphI

X - XbaI

Throughout this application various publications are referenced by mention of the first author and the
 15 year of publication within parentheses. Full citation of the references may be found at the end of the Specification as an annex, listed according to their alphabetical order immediately following the specification. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein.

20 The yeast molecule according to the present invention is characterized by containing an expression cassette which in turn is composed of three to four different components, being arranged in operable linkage in order to ensure efficient expression of a desired polypeptide, optionally followed by secretion of same. These components are defined to be the following :

25 a) A first DNA sequence serving as a regulon. The term "a regulon" as used throughout the application comprises any cis-acting DNA sequence involved in the regulation of expression of a given structural gene. The term thus embraces sequences preceding a given coding sequence, for example, a promoter and sequences which are recognised by transcription factors or other proteins involved in transcription regulation. The "first DNA sequence" is thus not limited to sequences corresponding to known promoters. Also included are DNA sequences corresponding to natural occurring regulons, which have
 30 undergone insertion, deletion or substitution events, but still retain their activity as regulon. Further the term "regulon" includes DNA sequences involved in regulation of transcription, which have been synthesised chemically or obtained by methods of gene technology.

35 b) An optional second DNA sequence coding for a signal peptide. The meaning of this second DNA sequence includes various DNA sequences, directing the secretion of any polypeptide containing the thus encoded peptide at its N-terminal end.

c) A third DNA sequence coding for a foreign protein. This coding sequence coding for the signal peptide in order to retain a proper reading frame for the third DNA sequence. The fusion thus requires application of methods or recombination DNA technology known to every person skilled in the art. For methods enabling to design proper fusions it is in general referred to Maniatis et al. (1982), wherein
 40 appropriate methods, e.g. various ways to treat restriction fragment ends, cloning of linker molecules and similar procedures are described in great detail.

45 The foreign protein coded for by the third DNA sequences may be any protein which to express there exists some need. Since the secretion system is capable of secretion not only of small molecules, but also of large proteins, expression of any desired protein should be possible. For examples it is referred to the discussion below.

50 d) Optionally a fourth DNA sequence serving as a terminator. As the terminator any sequence may be used, which efficiently terminates transcription in the respective host organism. Terminators may be for example sequences prone to formation of hairpin structures and/or polyadenylation sites. In a preferred embodiment the terminator is derived from the same gene as the second DNA sequence, i.e. the regulon, is derived from.

The four components are combined with each other using known techniques. Optionally the proper fusion will be verified for example by sequencing the boundaries.

55 The yeast cell according to the present invention contains at least one expression cassette comprising some or all of the above mentioned DNA sequences. It provides a convenient tool for the industrial expression of any desired protein.

In a preferred embodiment said first and/or second and/or fourth DNA sequence are derived from a gene coding for an amylolytic enzyme, for example α -amylase or glucoamylase, which enzymes in most organisms are induced upon contact with starch. The DNA sequences may be derived from a yeast of a

member of one of the genera Debariomyces, Saccharomyces, Lipomyces, Pichia, or Saccharomyces, but yeast of the genus Schwanniomyces are preferred.

5 Yeast species of the genus Schwanniomyces have an efficient expression and secretion apparatus, enabling them to grow on starch as a sole carbon source. Starch is hydrolysed to glucose by two amylolytic enzymes, secreted into the supernatant, namely α -amylase (α - 1,4-glucan 4-glucanohydrolase E.C.3.2.1.1) and glucoamylase (syn. amyloglucosidase) (α -1,4-glucan glucohydrolase, E.C.3.2.1.3.; with debranching activity E.C.3.2.1.9.). The amylolytic enzymes of Schwanniomyces occidentalis, formerly also called schwanniomyces castellii and Schwanniomyces alluvius (Price et al., 1978), are well documented (Oteng-Gyang et al., 1981; Sills et al., 1982, 1984a, 1984b; Wilson et al., 1982).

10 The genes for α - amylase and glucoamylase from a yeast of the genus Schwanniomyces have been disclosed by the present inventors in EP 87 110 370.1. However, at that time the DNA or peptide sequences directing secretion have not been identified. Furthermore their use for the establishment of an efficient expression and secretion system in yeast was not known then.

15 It is preferred, to use as a first DNA sequence part or all of a 1.8 kb BgIII-Xhol fragment which precedes the structural gene coding for the Schwanniomyces α -amylase, or part or all of a 1.3 kb BamHI-PvuII fragment preceding the structural gene coding for the Schwanniomyces occidentalis glucoamylase. Further if only smaller fragments are to be used, it is preferred, to use a DNA sequence comprising part or all of the DNA sequence corresponding to bases -1 to -540 of the region preceding the structural gene coding for α -amylase or part or all of the DNA sequence corresponding to bases -1 to -320 of the region 20 preceding the structural gene coding for glucoamylase. The respective DNA fragments are fully active as promoters, inducible by starch, dextrin, maltose.

It is obvious, that replacement of bases or base pairs, not involved in the transcriptional regulation, still are within the spirits of the present invention. Thus natural mutations or synthetic equivalents also are embraced by the present invention.

25 In yeast cells of the genus Schwanniomyces it is also possible to use promoters derived from yeast genes obtained from many other yeast genera. Preferred are regulons involved in the expression of ADH1, ADH2, PDC1, GAL1/10, PGK and GAPDH, or LAC4 which are obtained from Saccharomyces cerevisiae, Kluyveromyces Lactis or Schwanniomyces occidentalis.

30 Furthermore, it is possible to use viral regulons and/or terminators, for example regulons and terminators obtained from E.coli T-phages. The phages possess extraordinarily strong functional sequences for performance of their lytic functions. In a preferred embodiment sequences of phage T7 are used, which are regulated by expression of T7 RNA polymerase.

35 In order to increase the over all expression level and furthermore, in order to facilitate purification of produced polypeptides, it is most desirable, that the polypeptides are secreted into the culture medium. The present invention provides signal sequences having the invaluable advantage of being derived from genes of amylolytic and thus inducible enzymes, which upon induction have to be secreted very efficiently. A further advantage is, that induction of amylolytic enzymes does not require complicated media, lacking for example a specific amino acid or phosphate, but only require the culture to be transferred to a starch containing medium. Signal sequences, which are preferably used for secretion of large proteins include part 40 or all of at least one of the following peptides:

- a) MetArgPheSerThrGluGlyPheThrSerLysValValAlaAlaLeuAlaPheSerArgLeuValSerAla;
- b) MetArgPheSerThrGluGlyPheThrSerLysValValAlaAlaLeuAlaPheSer-ArgLeuValSerAlaGlnProllellePheAspMetArg;
- c) MetIlePheLeuLysLeuIleLysSerIleValIleGlyLeuGlyLeu ValSerAla;
- d) MetIlePheLeuLysLeuIleLysSerIleValIleGlyLeuGlyLeu ValSerAlaIleGinAlaAlaProAla;
- e) MetIlePheLeuLysLeuIleLysSerIleValIleGlyLeuGlyLeu ValSerAla-
IleGinAlaAlaProAlaSerSerIleGlySerSerAlaSerAla

45 In a further embodiment the above mentioned peptides are coded for by DNA sequences, which correspond to all or part of the following DNA sequences:

- 50 a) ATGAGATTTCAACTGAAGGATTACAAGTAAAGTTGTTGCAGCAATTAGCATTCTCAAGATT-GGTATCTGCT;
- b) ATGAGATTTCAACTGAAGGATTACAAGTAAAGTTGTTGCAGCAATTAGCATTCTCAAGATT-GGTATCTGCTCAACCGATTATTTTGACATGAGA;
- c) ATGATTTCTGAAGCTGATTAAGTATAGTAATTGGTTGGGATTA GTTAGTGCT;
- d) ATGATTTCTGAAGCTGATTAAGTATAGTAATTGGTTGGGATTA GTTAGTGCTATCCAAG-CAGCCCCCTGCC;
- e) ATGATTTCTGAAGCTGATTAAGTATAGTAATTGGTTGGGATTA GTTAGTGCTATCCAAG-CAGCCCCCTGCCCTTCGATTGGATCTAGTGCTTC GCA.

It will be understood, that the replacement of amino acids by residues having comparable properties and use of alternative codons in compliance with the possibilities provided by the genetic code will not have any impact on the yeast cell according to the present invention.

The polypeptide to be expressed in a yeast cell according to the present invention is coded for by a third DNA sequence. Said third DNA sequence may comprise natural or synthetic DNA, even DNA containing intervening sequences. Examples for proteins being expressed by the yeast cell according to the present invention comprise proteins of enormous importance for scientific or medical purposes, for example cellulase, interleukine, interferon, insulin like growth factor, lymphokine, human growth factor, nerve growth factor, aprotinin, insulin, hirudin, hormones, blood clotting factors, hepatitis B surface or core antigens, viral or bacterial vaccines or human granulocyte/macrophage colony stimulating factor.

The yeast cell according to the present invention may optionally comprise a terminator as component of said expression cassette. Preferred terminators are derived from genes of one of the following genera : Saccharomyces, Pichia, Hansenula, but preferably Schwanniomyces. Examples of preferred terminators are those derived from Schwanniomyces α -amylase gene or Schwanniomyces glucoamylase gene, part or all of which may be used. Such terminators are comprised by nucleotides 1537 to 1740 of the Schwanniomyces α -amylase gene or nucleotides 2875 to 3320 of the Schwanniomyces glucoamylase gene.

It is obvious, that in case of any of the DNA sequences mentioned modifications, which do not impair the biological function of the respective DNA fragment still are covered by the present application. There are numerous possibilities to change the DNA sequences mentioned above slightly without impairing the biological function of said fragment gene.

The yeast cell according to the present invention, carrying an expression cassette composed of the above discussed components, may be carried by a circular or linear vector, which optionally comprises one or more selective marker genes. The present inventors demonstrated, that a lot of marker genes so far used for transformation of Saccharomyces, for example TRP5, LEU2, ADE1, ADE2, HIS3, HIS4, URA3, LYS2, which may be obtained from Saccharomyces, Hansenula, Pichia or Schwanniomyces, are functional in Schwanniomyces occidentalis. Furthermore it is also possible to use the amylolytic properties of α -amylase or glucoamylase in order to select transformed organisms. The corresponding genes have been isolated and characterized. AMY1 and GAM1 are preferably obtained from Schwanniomyces.

The yeast cell according to the present invention may contain the expression cassette as an insert into one of the endogenous yeast chromosomes. Furthermore, there is however the possibility, that a DNA sequence capable of controlling autonomous replication and even also stable maintenance of the vector in the host organism, is introduced into the yeast cell. Said DNA sequences are the so called ARS sequences, capable of controlling autonomous replication and stable maintenance in the respective host organism. Said DNA sequences are preferably derived from Saccharomyces, Pichia Hansenula or Kluyveromyces, most preferred from Schwanniomyces.

In order to ensure effective replication in the prospective host organism, it is preferred to use an ARS, derived from the respective host organism.

The present invention provides one new SwARS sequence. The DNA sequence SwARS2 is capable of controlling autonomous replication and stable maintenance of the vector in a Schwanniomyces yeast cell. The detailed sequence of SwARS has not yet been determined. SwARS2 is localised in the Schwanniomyces genome in the 3' region of the glucoamylase gene, as shown for example in Fig. 10. SwARS2 is easy to identify and efficiently allows autonomous replication of any plasmid, exhibiting this sequence. The so far known Schwanniomyces autonomously replicating sequences, SwARS1 and SwARS2 are comprised on a ClaI-BamHI fragment (SwARS1) adjacent to the EcoRI-fragment shown in Fig 2a (see Fig. 10) and/or an EcoRI-BglII fragment contained in the EcoRI fragment shown in Fig 2a (SwARS2).

For the SwARS sequences it is also not necessary, in any case to use the sequence as it occurs naturally. DNA sequences, that have been obtained by any kind of modifying treatment, for example by deletion, insertion or substitution of one or more nucleotides or base pairs, are still within the scope of the present invention, provided the modifications retain or improve the biological function of the yeast cell according to the present invention.

In a preferred embodiment the yeast cell according to the present invention comprises a DNA sequence, which is homologous to genomic Schwanniomyces DNA. Provision of structures of homologous DNA enable the DNA fragment flanked by such homologous sequences to be inserted by homologous recombination. It is thus preferred to have homologous sequences, which do not represent any essential gene of the Schwanniomyces genomic DNA, but rather any gene, whose expression product may be supplemented by additives to the respective medium or were lack of the respective expression product does not have any serious impact on the transformed yeast cell.

If no SwARS sequence or any equivalent sequence, for example originating from any other yeast

species, is available, the expression cassette can be used without an autonomously replicating agent. In this case the expression cassette tends to integrate into the genome, for example via homologous recombination. Preferably there are several copies inserted into one or more chromosomes.

5 In this case it is preferred, to have multiple copies of the expression cassette inserted, in order to ensure simultaneous transcription and translation of several copies.

When the yeast cell according to the present invention is derived from a yeast of the genus Schwanniomyces the polypeptide products observed following expression of the respective foreign gene in said yeast cells exhibit glycosylation patterns, which closely resemble or even match those of the desired eucaryotic protein. Yeast cells of the genus Schwanniomyces are thus preferred for expression of 10 eucaryotic proteins.

15 The above discussed yeast cell according to the present invention can be used in a process for the production of a polypeptide, wherein a yeast host organism is cultivated under suitable conditions and the polypeptide is recovered in a manner known *per se*. The conditions of cultivation depend on the respective host organism used. Examples for cultivation conditions for yeast of the genus Schwanniomyces are provided in the examples below. The polypeptide, produced by the yeast according to the present invention, is recovered by conventional purification methods, which depend on the properties of the expressed protein, the availability of specific absorbing agents and so on.

20 In a preferred embodiment yeast cells of the species Schwanniomyces occidentalis are used as a host organism and are cultivated on starch,dextrin, maltose and/or plant biomass as the respective carbon source. As commonly known, these carbon sources are available at low costs.

25 Furthermore, there is a possibility to use cells of the genus Schwanniomyces for the production of single cell protein. The single cell protein may then be subjected to any further use as it is required.

In a preferred embodiment the polypeptide produced in a process according to the present invention is an amylolytic enzyme, for example an α -amylase or glucoamylase. These enzymes are commercially used 30 to debranch and degrade starch, which thereupon may be further processed, for example in brewery or baking processes. There is a high need for the provision of starch degrading enzymes.

35 In a further embodiment of the process according to the present invention production of a polypeptide may be achieved by providing expression cassettes as discussed above containing a yeast α -amylase or glucoamylase signal sequence and inserting the respective expression cassette into a yeast of one of the genera Saccharomyces, Kluyveromyces, Hansenula, Pichia or Schizosaccharomyces. Production and secretion 40 of foreign proteins in the respective yeast host organism is obtained by applying the appropriate inductive measure, whereupon the produced protein is secreted due to the presence of the yeast α -amylase or glucoamylase signal sequence. Since it is known from experiments performed by the present inventor, that these signal sequences are recognised in virtually any yeast genus, the α -amylase or glucoamylase signal sequences may be applied in many different yeast with success. Also in this case, it is preferred, to use the α -amylase or glucoamylase signal sequences derived from the respective genes of Schwanniomyces occidentalis.

45 In summary the yeast cells according to the present invention are well suited for transformation and expression of any desired foreign gene. As already outlined above, expression of prokaryotic as well as eucaryotic genes is possible. However, for expression of eucaryotic proteins yeast cells of the genus Schwanniomyces containing some or all of the DNA sequences mentioned above are the most preferred yeast cells.

45 CHARACTERISATION OF THE α -AMYLASE AND GLUCOAMYLASE GENE EXPRESSION IN DIFFERENT YEAST GENERA :

50 The N-termini of the deduced amino acid sequences of the α -amylase gene (Fig.1B) and glucoamylase gene (Fig.2B) exhibit the features of typical leader sequences of secretory proteins (Von Heijne 1983, Perlman and Halvorsson 1983). The N-terminal amino acids of mature α -amylase secreted by S. occidentalis are determined to be AspValSer. This indicates processing between Arg33 and Asp31 which is unusual and not according to the Von Heijne's model of site specificity for signal peptidase cleavage. This putative cleavage site was confirmed also for α -amylase expressed in S. cerevisiae, Pichia stipidis, K. lactis, S. pombe and H. polymorpha. However, in these yeast species processing is also found to occur between Ala 55 25 and Gln 26, resulting in the N-terminal sequence GinProlle.

55 α -amylase isolated from a culture of S. occidentalis migrates as a single band of 55 kDa on SDS polyacrylamide gels: following Endoglycosidase H treatment and subsequent gel electrophoreses a single band of 54 kDa is observed, indicating that only one of the two potential N-glycosylation sites of the protein

is used for glycosylation. It is noteworthy that high mannose glycosylation, as very often found by proteins secreted in S. cerevisiae is not accompanying secretion in S. occidentalis.

5 IDENTIFICATION OF THE TRANSCRIPTION INITIATION SITES AND PROMOTER FUNCTION OF THE α -AMYLASE AND GLUCOAMYLASE GENE.

By S1 mapping of polyA-mRNA (Sharp et al., 1980) the transcription initiation site of the α -amylase gene could be localised to be in the region of -42 to -30 (indicated by an interrupted line above the relevant sequence in Fig.1B) and the transcription initiation site of the glucoamylase gene was determined to be in the region -7 to -10 (underlined in Fig.2B).

CONSTRUCTION OF AN α -AMYLASE - GLUCOAMYLASE HYBRID GENE

15 In order to facilitate use of the α -amylase promoter and glucoamylase structural gene in further constructions additional restriction sites were inserted in front of the translation initiation codon of both genes using oligonucleotide directed mutagenesis as described in the AMERSHAM protocol. Correct mutagenesis was verified by sequencing according to Sanger (1977). The boundaries between the original 20 Schwanniomyces genes and the inserted polylinker are shown below :
 α -amylase :

** *

25 5' ..TAAAATAAAAGCTCGAGATGAGATT..3'.
XhoI

Glucoamylase:

30 * ***** * *
5' ..CTCATGACTGTGCGACGGATCCAAGATGATTTT..3'.
SalI BamHI

The manipulations resulted in plasmids M13 α Xho (Fig.3) and pMaGAM-B/S (Fig.4).

40 Thus, both the α -amylase promoter and the structural glucoamylase gene can be isolated from plasmid M13 α Xho and pMaGAM-B/S as suitable DNA fragments. The GAM gene was isolated from pMaGAM B/S as a 3.2 kb Sall fragment and ligated into the Xho site of M13 α Xho. The BgIII fragment harbouring the α -amylase promoter/GAM gene fusion was ligated into the single BamHI site of the S. cerevisiae vector YRp7 (Struhl et al., 1979) resulting in plasmid YRp7 α GAM (Fig 5). S. cerevisiae strain YNN27 was transformed 45 with this plasmid selecting for TRP prototrophy. Transformants secreted active glucoamylase into the culture supernatant (50 mU/ml) indicating that the α -amylase promoter fragment can direct expression and secretion of foreign proteins.

50 SECRESSION OF α -AMYLASE AND GLUCOAMYLASE IN DIFFERENT YEASTS USING SUITABLE PROMOTERS.

55 Expression of the α -amylase and glucoamylase gene and secretion of the gene products can be detected in K.lactis under control of the promoter of the α -galactosidase (LAC4) gene (Breunig et al., 1984). Expression of the α -amylase and glucoamylase gene and secretion of the both proteins can also be detected in S. pombe under control of the ADH1 promoter (Russel et al., 1983) or of the GAL1/10 promoters (Johnston and Davis 1984). After fusion with the GAL1/10 promoter (Johnston and Davis 1984), DHAS promoter (Janowicz et al., 1985), MOX promoter (Ledeboer et al., 1985) or FMDH promoter (EP 87 110

417.0) expression of the α -amylase and glucoamylase gene and secretion of both proteins can be detected in Hansenula polymorpha.

5 EXPRESSION AND SECRETION STUDIES IN S. OCCIDENTALIS USING THE CELLULASE EN-
DOGLUCANASE D (EGD) OF CLOSTRIDIUM THERMOCELLUM AS A MODEL FOR FOREIGN GENE
EXPRESSION.

10 As a first example for the expression of a foreign gene in S. occidentalis, the celD gene from C. thermocellum (Millet et al., 1985, Joliff et al., 1986b), which codes for a thermostable cellulase, namely an endoglucanase (EGD) was used. Advantages in using this system are :
 - specific reaction of EGD, which can easily be monitored
 - a rapid qualitative assay for colonies with EGD activity (see material and methods)
 - availability of antibodies against EGD for specific detection of translation products.

15

CHARACTERISATION OF THE GLUCOAMYLASE PROMOTER AFTER FUSION WITH THE celD GENE

20 Plasmids were constructed containing a replicon from S. occidentalis (SwARS1) (EP 87110370.1) the TRP5 gene from S. cerevisiae (Zalkin and Yanowski, 1982) as a selective marker and, in addition, a GAM/celD gene fusion under the control of different promoters. In the first step the 4.0 kb EcoRI-PvuII fragment from plasmid pBRSwARSGAM (Fig. 6a) was isolated and inserted into the 2296 bp pBR322 EcoRI-PvuII fragment, containing the amp gene and the bacterial origin, resulting in plasmid pBRPGAM (Fig.6a). In addition to the pBR322 sequence this plasmid carries 3.6 kb from the 5' non coding region of the GAM gene and the first 208 bp coding for the N-terminal part (including the signal sequence) of the glucoamylase. A 3.4 kb PvuII fragment from plasmid pCT603 (Joliff et al., 1986) containing the coding region of the celD gene missing the 5' 111 bp was inserted into the PvuII single site of pBRPGAM resulting in pBRGC1 (Fig.6b). E. coli transformed with this plasmid results in weak Carboxymethylcellulase (CMCase) activity, analysed by congo red staining (see material and methods) indicating that the glucoamylase promoter is slightly expressed in E. coli. For the construction of a S. occidentalis expression vector the plasmid pCJD5-1 (EP 87110370.1) was cleaved with BamHI/PstI and ligated with the 5.5 kb BglII-PstI fragment or 6.5 kb BamHI-PstI fragment from pBRGC1, resulting in pMPGC1-1 (Fig.6c) and pMPGC1-2 (Fig.6d), respectively. Both plasmids share an in frame fusion of GAM/celD but differ in the length of the 5' upstream region of the GAM gene. S. occidentalis strain NGA58 (trp5 ade) isolated after UV mutagenesis of strain NGA23 was transformed with these plasmids and transformants selected for tryptophan prototrophy and analyzed by means of congo red assay for cellulase activity. Transformants produced active EGD when grown under inducing conditions in 2% maltose (Fig 7a). By analysis with the congo red assay no activity could be detected under repressed conditions in 4% glucose (Fig. 7b). NGA58:pMPGC1-1 and NGA58:pMPGC1-2 transformants secrete active EGD into the culture supernatant when grown in maltose under induced conditions. The intact or complete glucoamylase promoter resides on plasmid pMPGC1-2 as shown by 20 times higher activity compared to the shorter promoter fragment in gene fusion of pMPGC1-1 (table 1). However the 0.3 kb promoter fragment still harbours regulatory units which lead to catabolite repression by glucose (Fig.7b). Comparison of the N-terminal GAM sequence to the signal peptidase cleavage sites of several other secretory proteins (Von Heijne 1983) reveals three potential signal peptidase cleavage sites after the amino acid residues Ala 19, Ala 25 and Ala 34. For determination of the N-terminal amino acid of the mature glucoamylase the protein was isolated for N-terminal amino acid sequencing. However the N-terminus is blocked and therefore could not be sequenced. To confirm the correct cleavage site of the GAM signal sequence in S. occidentalis, the regions between the potential signal peptidase cleavage sites and the PvuII gene fusion site are deleted in the GAM/celD fusion by in vitro mutagenesis to study the influence on secretion of active EGD.

STUDIES OF THE USE OF SUITABLE S. CEREVIAE PROMOTERS IN THE EXPRESSION OF FOREIGN GENES IN S. OCCIDENTALIS.

55

The ADH1 promoter (Hitzeman et al., 1981) was isolated as a 1.45 kb BamHI-Sall fragment from plasmid pFM2-1 (Müller et al., 1987) and ligated into plasmid pCJD5-1 (EP 87 110370.1) after cleavage with BamHI and Sall resulting in pMPADH1 (Fig.8a). The GAM gene was excised as a Sall fragment from

pJDcg-15 (see below) and inserted into the single Sall site of pMPADH1 (Fig. 8b) resulting in plasmid pMPAG (Fig. 8b). By the means of *in vivo* recombination (Ma et al., 1987) the GAM promoter from pMPGC1-2 (Fig 6d.) was replaced by the ADH1 promoter of pMPAG leading to plasmid pMPAGC (Fig. 8c). Plasmid pMPGC1-2 was linearized with BarnHI; the unique BarnHI site of pMPGC1-2 is localized between the TRP5 coding sequence and the glucoamylase promoter. The 2.75 kb Clal fragment of pMPAG containing the ADH1 promoter shares homologies to the TRP5 gene as well as to the GAM coding region up to position + 208. For *in vivo* recombination NGA58 was transformed with BarnHI linearized pMPGC1-2 together with approx. 10 fold excess of Clal fragment using the transformation protocol of Ito et al., 1983.

Recombinants were screened for their ability to hydrolyze CMC on 4% glucose. Under these conditions celD expression is repressed in transformants harbouring recircularized pMPGC1-2. From 146 transformants 7 colonies expressing cellulase in the presence of 4% glucose were isolated. NGA58 containing the "*in vivo*" constructed plasmid pMPAGC expresses active EGD constitutively (see Fig. 7). This result demonstrates that the newly constructed plasmid pMPADH1 serves as a vector for foreign gene expression.

In another experiment a recombinant plasmid was constructed by *in vivo* recombination to study the expression of the GAM/celD gene fusion under control of the PDC promoter (Das and Hollenberg, 1982). Therefore the 6.0 kb SphI-Aval fragment from plasmid pJDcg-15 (EP 87 110370.1) carrying the glucoamylase gene fused to the PDC promoter was subcloned into the respective restriction sites of YRpJD2 (EP 87 110370.1) resulting in plasmid pMPPG (Fig. 9a).

For *in vivo* recombination pMPPG was cleaved with Clal and used together with BarnHI linearized pMPGC1-2 for transformation of NGA58. Homologous recombination results in plasmid pMPPGC (Fig. 9b) harbouring a GAM-celD fusion under control of the PDC promoter. This construction leads to an expression in *Schwanniomyces occidentalis* NGA58 inducible by glucose and partly repressable by maltose (Table 1). Transformants were analysed for expression of active EGD using the qualitative congo red assay (Fig. 7). The results indicate that the 0.3 kb GAM promoter fragment leads to regulated expression, however less efficient than the 1.3 kb fragment (for comparison see table 1 and Fig. 2A). Expression under the ADH1 promoter leads to efficient constitutive expression. The expression level is comparable with that of induced expression directed by the 1.3 kb GAM promoter.

The fact that plasmids can be constructed by *in vivo* recombination is a proof for homologous recombination and hence offers the possibility for stable site directed integration into the genome of *S. occidentalis*, a prerequisite for the industrial production of foreign proteins.

The expression of the α -amylase gene and glucoamylase gene and secretion of the both gene products in *S. occidentalis* could also be achieved under control of the phosphoglycerate kinase (PGK) promoter (Dobson et al., 1982), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter (Holland and Holland 1979), copperchelatin (CUP1) promoter (Karin et al., 1984, Butt et al., 1984) and alcoholdehydrogenase 2 (ADR2 or ADH2) promoter (Russell et al., 1983, Beier et al., 1985) or galactokinase (GAL1/10) promoter (Johnston and Davis, 1984).

Construction of pJDcg-15 :

The GAM gene was isolated as a 3.2 kb BarnHI-Sall DNA fragment from plasmid pMaGAM B/S (Fig.4) and inserted into the respective restriction sites of plasmid pBM272 Johnston & Davis, 1984). The PDC promoter was isolated from plasmid pCP202 (Kellermann & Hollenberg, 1988) as a Sall-SphI fragment and ligated into the respective single sites of vector YRp7 (Struhl et al., 1979). To be able to isolate the PDC1 promoter as a BarnHI fragment the 3.2 kb Sall fragment of PMaGAM B/S containing the GAM gene was fused to the PDC promoter via the single Sall site. The resulting BarnHI fragment containing the PDC promoter was ligated into the single BarnHI site of pBM272 containing the GAM gene. The final plasmid is called pJDcg-15 (Fig. 8b).

50 EXPRESSION OF HUMAN GRANULOCYTE/MACROPHAGE COLONY STIMULATING FACTOR (hGM-CSF)

The gene coding for hGM-CSF (Cantrell et al., 1985) was obtained from British Biotechnology Ltd. as a HindIII-EcoRI fragment. Position +52 of hGM-CSF gene was fused to position + 102 of the GAM signal sequence under control of the ADH1 or GAM promoter. This fusion results in a hybrid protein in which the endopeptidase cleavage site of the GAM signal sequence is linked with a Met included in the synthetic gene offered by British Biotechnology Ltd., followed by the first amino acid of mature hGM-CSF (Ala 18).

This fusion was inserted into a *S. occidentalis* expression vector and transformed into NGA58. Western blot analysis revealed secretion of hGM-CSF protein.

5 EXPRESSION OF INTERLEUKINE-2

The gene coding for IL-2 (Taniguchi et al., 1983) was obtained from British Biotechnology Ltd., as a EcoRI-HindIII fragment. Position +61 of IL-2 gene was fused to position + 102 of the GAM signal sequence under control of the ADH1 or GAM promoter. This fusion results in a hybrid protein in which the 10 endopeptidase cleavage site of the GAM signal sequence is linked with a Met included in the synthetic gene offered by British Biotechnology Ltd., followed by the first amino acid of mature IL-2 (Ala 21). This fusion was inserted into a *S. occidentalis* expression vector and transformed into NGA58. Western blot analysis revealed secretion of IL-2 protein.

15

ISOLATION OF AN ADDITIONAL SwARS ELEMENT AND A NEW SELECTABLE MARKER

A new SwARS sequence (SwARS2), localized downstream of the coding region of the GAM gene, could be identified. To analyze the function of SwARS2 a vector was constructed containing the Trp5 gene and 20 SwARS2 in pBR322, resulting in pMPTS2-A and pMPTS2-B, respectively (Fig. 10). For the construction of pMPTS2-A and pMPTS2-B the 5.5 kb BamHI - BgIII fragment of pBRSwARSGAM, constructed by insertion of the EcoRI-fragment shown in Fig. 2a into the single EcoRI site of plasmid pBRSwARS1, (disclosed in EP 87 110370.1), was isolated and ligated with 3.2 kb BamHI TRP5 fragment obtained from YRpJD2. High frequency transformation of *S. occidentalis* is obtained using this plasmid.

25 As an additional selectable marker the LEU2 gene of *S. occidentalis* was isolated. The LEU2 gene, coding for isopropyl malate dehydrogenase, was cloned by functional complementation of the mutant AH22 (his4leu2) (Hinnen et al., 1978) of *S. cerevisiae* by transformation with a cosmid genomic library from *S. occidentalis*.

The LEU2 gene was found to reside on a 9 kb EcoRI fragment of *Schwanniomyces* genomic DNA; it's 30 function could be abolished by insertion of the TRP5 gene of *S. cerevisiae*. The disrupted LEU2 gene was integrated into the genome of NGA58 by homologous recombination resulting in a new strain NGA581 (TRP5, LEU2, and ADE). An analogous experiment with the cloned HIS4 gene of *S. occidentalis* (EP 87 110 370.1) led to a strain NGA58h (TRP5, HIS4, ADE).

35

IMPROVED EXPRESSION OF HETEROLOGOUS GENES USING THE T7 RNA POLYMERASE AND T7 PROMOTER AND TERMINATOR FOR THE EXPRESSION OF FOREIGN GENES IN *S. OCCIDENTALIS*

T7 RNA polymerase (Fuerst et al., 1986) can be expressed in *S. occidentalis* after fusion of the 40 structural gene (Dunn and Studier, 1984) using the BamHI restriction site near the translation initiation codon with suitable promoters asa-amylase, GAM (0.3 kb fragment) or PDC and homologous integration into the genome via any homologous cloned gene, e.g. HIS4, LEU2, AMY1 and GAM. A suitable fragment, containing the fusion flanked by homologous cloned sequences can be isolated and used together with pCJD5-1 (Fig. 6c) for co-transformation of NGA58, selecting on YNB containing 0.5% casaminoacids. 45 Colonies containing the integrated T7 RNA polymerase gene can be identified by Southern analysis after isolation of transformants mutated in the target gene.

For the expression of foreign genes a *S. occidentalis* expression vector was constructed containing SwARS2, the ColE replication origin of *E. coli*, a suitable selective marker for *S. occidentalis* (e.g. TRP5, HIS4, LEU2) and a cassette containing the T7 polymerase promoter and terminator sequences isolated from 50 plasmid pAR2529 (Fuerst et al., 1986), separated by the polylinker sequence from M13mp19. To study the efficiency of the T7 system we expressed a GAM/celD fusion (GAM signal sequence and structural celD gene obtained as a BamHI-Asp 718 fragment from pMPGC1-2) under control of the T7 promoter by insertion into the BamHI-Asp718 site of the polylinker sequence. Using this system active cellulase is secreted into the culture medium.

55

MATERIALS AND METHODS

1. The microorganisms used are as follows :

Schwanniomyces occidentalis NGA23 : (DSM 3792)

Schwanniomyces occidentalis NGA58

5 Kluyveromyces Lactis SD11 : (DSM 3795)

Schizosaccharomyces pombe LEU1-32, HIS5-303 (DSM 3796)

Saccharomyces cerevisiae YNN27 (URA3-52, TRP1-298, GAL2)

10 The Escherichia coli strain used is as follows E. coli HB101 F-, hsd S20 (r_B- m_B -), recA13, ara-14, proA2, lacY1, galK2, rpsL20 (Sm^R), xyl-5, mtl-1, supE44)2. Culture media :

15 Schwanniomyces occidentalis strain NGA58 (isolated by UV mutagenesis of strain NGA23) was grown at 30 °C in YNB (0.67% yeast nitrogen base without amino acids) supplemented with appropriate amino acids and with 2% of soluble starch when indicated.

20 Strains were grown under conditions as described above for Schwanniomyces occidentalis with the replacement of 2% soluble starch by 2% glucose, where indicated.The culture media for S. occidentalis and Hansenula polymorpha were buffered with 0.2 M NaPO₄ buffer pH 6.2; those for S. cerevisiae and K. lactis were buffered with 0.1 M citrate buffer pH 6 and those for S. pombe with 0.05 M acetate buffer pH 6.25 The pH optimum for the cellulase (Joliff et al., 1986a), α -amylase and glucoamylase (Wilson and Ingledew, 1982) is approx. pH 6.

E. coli HB101 (Bolivar et al., 1977) was grown in LB medium (Maniatis et al., 1982) with penicillin G (150 ug/ml).

30

3. Miscellaneous methods

Plasmid DNA was purified either by CsCl gradient centrifugation (Maniatis et al., 1982) or by rapid alkaline extraction of plasmid DNA described by Birnboim and Doly (1979).

35 Yeast crude extracts were prepared by the method of Schatz (1979). Yeast minilysates were prepared by the method of Sherman et al., (1983).

DNA fragments were isolated by the "low melting agarose" procedure as described by Gafner et al., (1983). Southern hybridization was carried out as described by Southern (1975).

40 Yeast transformation was performed according to Klebe et al. (1983) or Ito et al. (1983). The transformants or integrants were tested for expression and secretion of cellulase using either the qualitative congo red assay (Teather and Wood, 1982: halo formation on carboxymethylcellulose agar plates) or a quantitative cellulase assay according to Joliff et al. (1986a). One unit (U) is defined as the amount of enzyme that released 1 umol para-nitrophenol per min at 60 °C. Western analysis was performed as described by Towbin et al. (1979).

45 The transformants or integrants were tested for expression and secretion of α -amylase using either a standardized α -amylase enzyme test from Merck, W. Germany or a qualitative starch degradation test (halo formation on starch agar plates after staining with iodine), as follows : in this test the rate of formation of 2-chloro-4-nitrophenol is determined by photometry at 405 nm in 0.1 M potassium phosphate at 37 °C. The enzyme unit (U) is defined as the amount of enzyme catalysing the formation of 1 umol 2-chloro-4-nitrophenol per min at 37 °C.50 Glucoamylase activity was measured by a stop assay method: After incubation of the sample in 10% soluble starch in 0.05M KH₂PO₄-NaOH (pH 5.0) at 50 °C the amount of glucose produced is determined by the glucose dehydrogenase method (system glucose Merck). The quantity of NADH formed is proportional to the glucose concentration. The enzyme unit (U) is defined as the amount of enzyme catalysing the formation of 1 umol glucose/min at 50 °C.

TABLE 1

| | Transformant | OD _{600 nm} | EDG-activity mU/ml |
|----|--------------------------------------------------------------------------------------------------------------|----------------------------|--------------------------------|
| 5 | NGA58: pMPGC1-1 (0.3 kb promoter) | 2.3 5.3 | 0.12 0.73 |
| 10 | NGA58: pMPGC1-2 (1.3 kb GAM promoter) | 2.0 7.9 | 0.53 1.83 |
| 15 | NGA58: pMPAGC ADH1 promoter | 3.0 5.9 | 0.52 1.07 |
| 20 | NGA58: pMPPGC PDC1-promoter | 2.2* 4.5* 2.9 7.2 | 0.40* 0.64* 0.19 0.31 |
| 25 | Transformants were grown in YNB, 0.5% Casaminoacids, 2% maltose, 20 mg/l adenine and 0.2 M NaP buffer pH 6.2 | | |
| | * : values for transformants grown in 4% glucose | | |

30 LIST OF REFERENCES

Beier et al. (1985), Mol. Cell. Biol. 5, 1743-1749.
 Birnboim & Doly (1979), Nuc. Acids Res. 7, 1513-1523.
 Bitter et al. (1984), Proc. Natl. Acad. Sci. USA 81, 5330-5334.
 35 Bolivar et al. (1977), Gene 2, 75-93.
 Breunig (1984), NUCI. Acids Res. 12, 2327-2341.
 Butt et al. (1984), Proc. Natl. Acad. Sci. USA 81, 3332-3336.
 Cantrell et al. (1985), Proc. Natl. Acad. Sci. USA 82, 6250-6254.
 Das & Hollenberg (1982), Curr. Genet. 6, 123-128.
 40 Dobson et al. (1982), Nucleic Acids Research 10, 2625-2637.
 Dunn & Studier (1984), Proc. Natl. Acad. Sci. USA 81, 2035-2039.
 Emr et al. (1983), Proc. Natl. Acad. Sci. USA 80, 7080-7084.
 Fuerst et al. (1986), Proc. Natl. Acad. Sci. USA 83, 8122-8126.
 Gafner et al. (1983), Embo J. 2, 583-591.
 45 Hinnen et al. (1978), Proc. Natl. Acad. Sci. USA 75, 1929-1933.
 Hitzeman et al. (1981), Nature 294, 717-722.
 Holland & Holland (1979), J. Biol. Chem. 254, 5466-5474.
 Ito et al. (1983) J. Bacteriol. 153, 163-168.
 Janowicz et al. (1985), Nucleic Acids Res. 9, 3043-3062.
 50 Johnston & Davis (1984), Mol. Cell. Biol. 4, 1440-1448.
 Joliff et al. (1986a), Bio/Technology 4, 896-900.
 Joliff et al. (1986b), NUCI. Acids Res. 14, 8605-8613.
 Karin et al. (1984), Proc. Natl. Acad. Sci. USA 81, 337-341.
 Kellermann & Hollenberg (1988), Curr. Genetics 14, 337-344.
 55 Klebe et al. (1983), Gene 25, 333-341.
 Kramer et al. (1984), Nucl. Acids. Res. 12, 9441-9456.
 Kurjan & Herskowitz (1982), Cell 30, 933-943.
 Ledeboer et al. (1985), Nucl. Acids. Res. 9, 3063-3082.

Ma et al. (1987), *Gene* 8, 201-216..

Maniatis, Fritsch & Sambrook (1982), *Molecular cloning: A laboratory manual*, Cold Spring Harbour Laboratory press, New York.

Millet et al. (1985), *FEMS Microbiol. Lett.* 29, 145-149.

5 Müller et al. (1987), *Mol. Gen. Genetics* 207, 421-429.

Oteng-Gyang et al. (1981), *Zeitschrift allgemeine Mikrobiologie* 21, 537-544.

Perlman et al. (1983), *J. Mol.* 167, 391-409.

Price et al. (1978), *Microbiol. Rev.* 42, 161-193.

Russell et al. (1983), *J. Biol. Chem.* 258, 2674-2682.

10 Sanger et al. (1977), *Proc. Natl. Acad. Sci. USA* 74, 5 463-5 467.

Schatz (1979), *Meth. Enzymol.* LVI, 40-50.

Sharp et al. (1980), in: *Methods Enzymol.* 65,

Sherman et al. (1983), *Methods in yeast genetics* in C.S.H. Laboratory, C.S.H. New York, 119.

Sills & Stewart (1982), *J. Inst. Brew.* 88, 313-316.

15 Sills et al. (1984 a), *J. Inst. Brew.* 90, 311-314.

Sills et al. (1984 b), *APPL. Microb. Biotechnol.* 20, 124-128.

Southern (1975), *J. Mol. Biol.* 98, 503-517.

Stinchcomb et al. (1980), *Proc. Natl. Acad. Sci. USA* 77, 4 559-4 563.

Struhl et al. (1979), *Proc. Natl. Acad. Sci. USA* 76, 1035-1039.

20 Taniguchi et al. (1983), *Nature* 302, 305-309.

Teather & Wood (1982), *Appl. Env. Microbiol.* 43, 777-780.

Towbin et al. (1979), *Proc. Natl. Acad. Sci. USA* 76, 4350-4354.

von Heijne (1983), *Eur. J. Biochem.* 133, 17-21.

Wilson & Ingledeew (1982), *Appl. Environ. Microbiol.* 44, 301-307.

25 Zalkin & Yanowsky (1982), *J. Biol. Chem.* 257, 1491-1500.

Claims

30 1. A yeast cell of the genus Schwanniomyces,
 characterized in that
 said yeast cell contains at least one expression cassette comprising :
 a) a first DNA sequence serving as a regulon,
 b) optionally a second DNA sequence coding for a signal peptide
 35 c) a third DNA sequence coding for a foreign protein, and
 d) optionally a fourth DNA sequence serving as a terminator.

2. The yeast cell according to claim 1,
 characterized in that
 40 said first and/or second and/or fourth DNA sequence are derived from a gene coding for an amylolytic enzyme.

3. The yeast cell according to claim 2,
 characterized in that
 said amylolytic enzyme is an α -amylase or glucoamylase.

45 4. The yeast cell according to any of claims 1 to 3,
 characterized in that
 said first and/or second and/or fourth DNA sequences are derived from a yeast of a member of the genera Debariomyces, Saccharomycopsis, Lipomyces, Pichia, or Saccharomyces, preferably Schwanniomyces.

5. The yeast cell according to claim 4,
 50 characterized in that
 said yeast is Schwanniomyces occidentalis.

6. The yeast cell according to any of claims 1 to 5,
 characterized in that
 55 said first DNA sequence is comprised by a 1.8 kb BgIII-Xhol-fragment preceding the structural gene coding for the Schwanniomyces α -amylase or the 1.3 kb BamHI-PvuII fragment preceding the structural gene coding for the Schwanniomyces occidentalis glucoamylase.

7. The yeast cell according to claim 5,
 characterized in that

said first DNA sequence is comprised by part or all of the DNA sequence corresponding to bases -1 to -540 of the region preceding the structural gene coding for α -amylase or part or all of the DNA sequence corresponding to bases -1 to -320 of the region preceding the structural gene coding for glucoamylase.

8. The yeast cell according to any of claims 1 to 5,

6 characterized in that

said first DNA sequence corresponds to one of the following regulons :

a) ADH1,ADH2, PDC1, GAL1/10, PGK, GAPDH, the regulon being preferably obtained from Saccharomyces cerevisiae

b) LAC4 the regulon being preferably obtained from Kluyveromyces lactis, or

10 c) corresponding regulons, preferably obtained from Schwanniomyces.

9. The yeast cell according to any of claims 1 to 5,

characterized in that

said first and/or fourth DNA molecule corresponds to a viral promoter and/or terminator, preferably from E. coli phage T7.

15 10. The yeast cell according to any of claims 1 to 9,

characterized in that

said second DNA sequence is coding for all or part of at least one of the following peptides :

a) MetArgPheSerThrGluGlyPheThrSerLysValAlaAlaAlaLeuAlaPheSerArgLeuValSerAla; LeuAlaPheSer-

b) MetArgPheSerThrGluGlyPheThrSerLysValValAlaAla

20 ArgLeuValSerAlaGlnProllellePheAspMetArg;

c) MetIlePheLeuLysLeuIleLysSerIleValIleGlyLeuGlyLeu ValSerAla;

d) MetIlePheLeuLysLeuIleLysSerIleValIleGlyLeuGlyLeu ValSerAlaAlaGlnAlaAlaProAla;

e) MetIlePheLeuLysLeuIleLysSerIleValIleGlyLeuGlyLeu ValSerAlaAlaGlnAlaAlaProAlaSerSerAlaSerAla

25 11. A yeast cell according to claim 10,

characterized in that

the DNA sequence coding for said peptide corresponds to part or all of one of the following DNA sequences:

a) ATGAGATTTCAACTGAAGGATTACAAGTAAAGTTGTTGCAGCAATT TTAGCATTCTCAAGATT-

30 GGTATCTGCT,

b) ATGAGATTTCAACTGAAGGATTACAAGTAAAGTTGTTGCAGCAATT TAGCATTCTCAAGATT-

GGTATCTGCTCAACCGATTATTTGALATGAGA;

c) ATGATTTCTGAAGCTGATTAAGTATAGTAATTGGTTGGGATTA GTTAGTGCT;

d) ATGATTTCTGAAGCTGATTAAGTATAGTAATTGGTTGGGATTA GTTAGTGCTATCCAAG-

35 CAGCCCCCTGCC;

e) ATGATTTCTGAAGCTGATTAAGTATAGTAATTGGTTGGGATTA GTTAGTGCTATCCAAG- CAGCCCCCTGCCCTTCGATTGGATCTAGTGCTTC GCA.

12. The yeast cell according to any of claims 1 to 11,

characterized in that

40 said third DNA sequence coding for a foreign protein is a natural or synthetical DNA sequence encoding a cellulase, interleukine, insulin like growth factor, interferon, lymphokine, human growth factor, nerve growth factor, aprotinin, insulin, hirudin, hormones, blood clotting factors, hepatitis B surface or core antigens, viral or bacterial vaccines or human granulocyte/macrophage colony stimulating factor.

13. The yeast cell according to any of claims 1 to 12,

45 characterized in that

said fourth DNA sequence originates from a yeast of a member of the genera Saccharomyces, Pichia, Hansenula, preferably Schwanniomyces.

14. The yeast cell according to claim 13,

characterized in that

50 said fourth DNA sequence corresponds to part or all of the terminator of the Schwanniomyces α -amylase gene or part or all of the terminator of the Schwanniomyces glucoamylase gene.

15. The yeast cell according to claim 14,

characterized in that

said terminator is comprised by nucleotides 1537 to 1740 of the Schwanniomyces α -amylase gene or nucleotides 2875 to 3320 of the Schwanniomyces glucoamylase gene.

55 16. The yeast cell according to any of claims 1 to 15,

characterized in that

said first and/or second and/or third and/or fourth DNA sequence has been modified by insertion or deletion

or substitution of one or more nucleotides while the biological activity of the DNA sequence is retained or improved.

17. The yeast cell according to any of claims 1 to 16,
characterized in that

5 said expression cassette is carried by a circular or linear vector, which optionally comprises one or more selective marker genes.

18. The yeast cell according to claim 17,
characterized in that

said vector comprises any of the following selective marker genes :

10 TRP5, LEU2, ADE1, ADE2, HIS3, HIS4, URA3, LYS2, preferably obtained from Saccharomyces, Hansenula Pichia or Schwanniomyces, AMY1 or GAM1, preferably obtained from Schwanniomyces.

19. The yeast cell according to any of claims 17 and 18,
characterized in that

said vector further comprises a DNA sequence capable of controlling autonomous replication and stable
15 maintenance of the vector in the host organism.

20. The yeast cell according to claim 19
characterized in that

said DNA sequence is derived from the genome of a member of the genera Saccharomyces, Pichia, Hansenula or Kluyveromyces, preferably Schwanniomyces.

20 21. A yeast cell according to any of claims 19 or 20,
characterized in that

said DNA sequence is selected from the autonomously replicating sequences ARS, preferably an ARS derived from the respective host organism.

22. The yeast cell according to claim 21,
25 **characterized in that**

said DNA sequence is SwARS1 or SwARS2, capable of controlling autonomous replication and stable maintenance of the vector in Schwanniomyces.

23. The yeast cell according to claim 22,
characterized in that

30 said DNA sequences are comprised on a Clal-BamHI fragment (SwARS1) or a EcoRI-BamHI-fragment (SwARS2) of Schwanniomyces genomic DNA.

24. The yeast cell according to any of claims 19 to 23,
characterized in that

said DNA sequence has been modified by deletion, insertion or substitution of one or more nucleotides,
35 while retaining or improving its biological function.

25. The yeast cell according to any of claims 1 to 24,
characterized in that

said yeast cell comprises any DNA-sequence homologous to genomic Schwanniomyces DNA, preferably homologous DNA-sequences flanking the expression cassette.

40 26. The yeast cell according to any of claims 1 to 25,
characterized in that

said expression cassette is integrated into the genome, optionally in multiple copies, preferably via homologous recombination.

27. The yeast cell according to any of claims 1 to 26,
45 **characterized in that**

said yeast cell is derived from the genus Schwanniomyces and is capable of glycosylation.

28. A process for the production of a polypeptide, wherein a yeast host organism is cultivated under suitable conditions and the polypeptide is recovered in a manner known per se,
characterized in that

50 said yeast host organism is a yeast cell according to any of claims 1 to 27.

29. The process according to claim 28
characterized in that

yeast cells of the species Schwanniomyces occidentalis are used as a host organism and are preferably cultivated on starch,dextrin, maltose and/or plant biomass.

55 30. The process according to any of claims 28 or 29,
characterized in that

yeast cells of the genus Schwanniomyces are used for the production of single cell protein.

31. The process according to any of claims 28 to 30,

characterized in that

 said polypeptide is α -amylase or glucoamylase.

 32. The process according to claim 28,

characterized in that

5 the signal sequence of a yeast α -amylase or glucoamylase gene is used for the production and secretion of foreign protein in yeast of the genera Saccharomyces, Kluyveromyces, Hansenula, Pichia or Schizosaccharomyces.

 33. Use of a yeast cell according to any of claims 1 to 27 for transformation and expression of foreign genes.

10

15

20

25

30

35

40

45

50

55




FIG. 1A

FIG. 1B,1

GGTACCTGA

-340 GCTAAATTAA GAAACCGGCTA TAGATCCGCT TGTCTAAAGA AGAGATAATG AAGAAACAA

-480 TTAACCGAAGC ACTCTTATTA AGTTTTTTC TATTTCTTT TGCTCTACT TCAATAATT

-420 ATCTAAATTG TATTGTGCCGT TAGATCAGAA TGTACTGATA ACAGAGAGTA TTATCATAACA

-360 CTTTGATT TCAAAAGGGG GAATCAAAAG CATACTGAT CAAACCCCTTG GTTATTGAT

-300 GCAATTAAAGG TTTGTAATCGT TCTTACCGAT CCATCATTAT ACCCCACACG GTTTCATGGT

-240 ATGTAAGGTGTT TCAATAGTG AAGTACAATG AATGTTTTGG TAATGCTGTA TGTTGGATCAG

-180 TAATTATGTT AAACAATTAA GTCTGAAAT TTATTAAT TTTACCTACA ATTAAGCCG

-120 AAATCCAATC GAAGGGTGCCG CCCAGCTGGT GTATAATTAA CTCTTGAAT TCAAGTTGAA

-60 CGTTGATCTC TCTAAAGCAA AGCTGTTATT CTACAATACT AAATAAAATA AAAGCAAGAC

-1

10 ATGAGATTCAACTGAAGGATTACAAGTAAAGTTGTTGCAGCAATTAGCATTCTCA
 Met Arg Phe Ser Thr Glu Gly Phe Thr Ser Lys Val Ile Val Ile Leu Ala Phe Ser
 20 30 40 50 60
 AGATTGGTATCTGCTCAACCGATTATTGACATGAGAGATGGCTCGTCAGCTGAT
 Arg Leu Val Ser Ala Gln Pro Ile Phe Asp Met Arg Asp Val Ser Ser Ala Asp
 70 80 90 100 110 120
 130 140 150 160 170 180
 AAATGGAAAGACCAATTGATTACTGTTAAATCGTTACTGATAGGTTGCAGATCTGATGGC
 Lys Trp Lys Asp Gln Ser Ile Tyr Gln Ile Val Thr Asp Arg Phe Ala Arg Ser Asp Gly
 ★
 190 200 210 220 230 240
 TCGACCACAGCTGACTGTTAGTGAGTGGCAAGTACTGGTGGATCTTATAAAGGG
 Ser Thr Ala Asp Cys Leu Val Ser Asp Arg Gly Tyr Cys Gln Ser Tyr Lys Gly
 250 260 270 280 290 300
 ATTATCGACAAGGTTGGATTATTCAAGGGTATGGGTTCACTGCGATCTGGATCTCCCCA
 Ile Asp Lys Leu Asp Tyr Ile Gln Gln Met Gln Met Gln Phe Thr Ala Ile Trp Ile Ser Pro

310 320 330 340 350 360
 GTTGTGAGCAAATTCCCTGACAATTACTGCTTATGGTTATGCTTACCATGGTTATTGGATG
 ValValGluGinIleProAsnThrAlaTyrGlyTyrAlaTyrHisGlyTyrTrpMet
 370 380 390 400 410 420
 AAAAATTGATGAATTGAAACACTAATTGGTACCGCTGATGAATTGAAACAATTAGCT
 LysAsnIleAspGluLeuAsnThrAsnThrAsnPheGlyThrAlaAspGluLeuLysGlnLeuAla
 430 440 450 460 470 480
 AGCGAAATTGCATTCCAGAACGATGTTATTGATGGTCACGTTACACCATTTATGCT
 SerGluLeuHisSerArgSerMetLeuMetValAspValValTyrAsnHistYrAla
 490 500 510 520 530 540
 TGGAACGGAGATGGTTCAAGCGTAGATTCTAGTTCACTCCATTCAATCAACAAATCT
 TrpAsnGlyAspGlySerSerValAspTyrSerSerPheThrProPheAsnGlnGlnSer
 550 560 570 580 590 600
 TACTTCCACGATTATTGTTGATTACAAATTATAATGATCAAACCAATGTTGAAGATTGT
 TyrPheHisAspTyrCysLeuIleThrAsnTyrAsnAspGlnThrAsnValGluAspCys
 610 620 630 640 650 660
 TGGGAAGGTGATACTGAAAGTCTCCAGATTAAAGTACCGAGGATAATGAAGTTATA
 TrpGluGlyAspThrGluValSerLeuProAspLeuSerThrGluAspAsnGluValIle

670 680 690 700 710 720
 GGAGTATTCAAACCTGGGTGTCAGATTGTTCAAACATTCAATCGATGGTTAAGA
 GlyvalPheGlnThrTrpValSerAspPheValGlnAsnTyrSerIleAspGlyLeuArg
 730 740 750 760 770 780
 ATTGATAGTGCAAGGCACGTAGATAACCGCTTCATTAAACGAAAGTTGAGGACGGCTCTGGT
 IleAspSerAlaLysHisValAspThrAlaSerLeuThrLysPheGluAspAlaSerGly
 790 800 810 820 830 840
 GTTATAACTTAGGTGAAGTTTATCAAGGAGATCCAACCTTATACCTTGTCATATCAGAAAT
 ValTyrAsnLeuGlyGluValTyrGlnGlyAspProThrTyrThrCysProTyrGlnAsn
 850 860 870 880 890 900
 TATATGAAAGGAGTTACCAACTATCCATTACATCCAGTATATAGATTCTTCAGTGAT
 TyrMetLysGlyValThrAsnTyrProLeuTyrTyrProValTyrArgPhePheSerAsp
 910 920 930 940 950 960
 ACTTCGGCGACTTCCAGTGAATTCAATGATCTCCACGTTACAGTCATCTTGTTCG
 ThrSerAlaThrSerGluLeuThrSerMetIleSerThrLeuGlnSerSerCysSer
 970 980 990 1000 1010 1020
 GACGTCTCTTGTGGGAAACCTTATTGAAACCATGACCAAGTTAGATTTCATCAGTT
 AspValSerLeuGlyAsnPheIleGluAsnHiAspGlnValArgPheProSerVal
 1030 1040 1050 1060 1070 1080
 ACCCTCAGACACATCCCTTGATTAAAGAATGACATGGCTTTATAATTGGGTGATGGTATC
 ThrSerAspThrSerLeuIleLysAsnAspMetAlaPheIleIleLeuGlyAspGlyIle

1090 1100 1110 1120 1130 1140
 CCAATTATTATGGCCAAAGAACAACTCAATGGGGATCCGATCTGCCAATAGA
 ProlineTyrTyrGlyGluGlyLeuAsnGlySerAspProAlaAsnArg
 1150 1160 1170 1180 1190 1200
 GAAGCTTTATGGTTAAGTGGATAATAACCGGATTCAGAATACTACGAGCTAATCAGTAAA
 GluAlaLeuTripleuSerGlyTyrAsnThrAspSerGluTyrTyrGlyLeuIleSerLys
 1210 1220 1230 1240 1250 1260
 CTAATCAAATAAGGCTTAAAGCTATTAAAGAAGGGATTCTGCCTATTCAACTACAAATCC
 LeuAsnGlyIleArgAsnGlnAlaIleLysLysAspSerAlaTyrSerThrTyrLysSer
 1270 1280 1290 1300 1310 1320
 TCAGTTGGTTCTCTCAGACCACCTATAAGCCACTAGGAAGGGTAGCGATGCTAATCAA
 SerValValSerSerAspHistYrIleAlaThrArgLysGlySerAspAlaAsnGln
 1330 1340 1350 1360 1370 1380
 -TGATTCATTTTAATAATTAGGGTCAAAACGGGTCACAGGGATATTACTGTCAAGAAC
 LeuIleSerIlePheAsnAsnLeuGlySerAsnGlySerGlnAspIleThrValSerAsn
 1390 1400 1410 1420 1430 1440
 ACCGGCTATTCTAGTGGTGTATAAGTTATCGATATTCTGCATTTCGTTTTAGCT
 ThrGlyTyrSerSerGlyAspLysValIleAspIleSerCysAsnSerValLeuAla
 1450 1460 1470 1480 1490 1500
 GGTGACTCCGGAAAGCTTATCTGTATCAATTCTGGTGGAAATGCCACAAAGTTACGGCTCCG
 GlyAspSerGlySerValSerIleSerLeuSerValSerGlyMetProGlnValTyrAlaPro




FIG. 2B₁

EP 0 394 538 A1

-310
AGATCTACATTAAACCCAG

-230
TCCTACTCAGATATTGAACTATACCCATTCTTACCCATTATCCATGACCCGCATCGA

-200
AATTTCAAGGATTTCGAGGAAATTCTCTTCTAAAGTATTACGAAAGTATTGATTCA

-150
ATTACTACGGAAACTACTCATATGGTAGTAACTGGAGAATTGAAATTGAAATTAAATT

-100
GCGAAGTTATAATAGTTGGCAAACCTGGAGAATTTCATTATTGGGAAATAATAAA

-50
TAAGGGCAABTATCCATTGAAATTAAATGAACTCATGACTTATTATAACCAAGCAAG
-1

10 20 30 40 50 60
 ATGATTCTGAAAGCTGATTAAAGTATAGTTAATTGGTTGGGATTAGTTAGTGCCTAC
 Met Ile Phe Leu Ile Lys Leu Ile Lys Ser Ile Val Ile Gly Leu Gly Leu Val Ser Ala Ile
 ★
 70 80 90 100 110 120
 CAAGCCAGCCCCCTGCCTTCGATTGGATCTAGCTCTAGCTCAAGTGGAGGT
 Gln Ile Ala Pro Ala Ser Ser Ile Gly Ser Ser Ser Ser Ser Glu Ser
 ★
 130 140 150 160 170 180
 TCTCAGGGCTACAACTCCCAATGATGATTAACATTAACAAATTCCCTAAATATCTTT
 Ser Gln Ile Thr Ile Pro Asn Asp Val Asp Val Asp Val Asp Val Asp Val Asp Val
 ★
 190 200 210 220 230 240
 AATGACTCTGCTGTCATGCTAAATGCAAGCTGCTAAAGGGTATGACTTGGTAAATGTTACT
 Asn Asp Ser Ala Val Val Asp Ala Asn Ala Asn Ala Asn Ala Asn Val Thr
 ★
 250 260 270 280 290 300
 AATACTCCAAAGGGATTAACTTAACTGCTTAAACCGGTATCTTAAATTAAAGAAGCTACCAAAATTATGGT
 Asn Thr Pro Arg Gly Leu Thr Gly Ile Gly Leu Lys Leu Lys Glu Val Asp Thr Arg Glu Asn Val
 ★
 310 320 330 340 350 360
 TATGATTCTGATTAAACTTAACCTGTTGAAACTGCTGATAACCAAGATTAAACGTT
 Tyr Asp Phe Asp Tyr Leu Asn Leu Thr Val Glu Tyr Gln Ile Asp Thr Arg Glu Asn Val
 ★
 370 380 390 400 410 420
 CATATTGAACTGAACTGATTCTGATGTTAGTTAGGCTTACCAAGAGCTTACCAAGATTAAACGTT
 His Ile Glu Pro Thr Asp Leu Asp Val Phe Val Leu Pro Glu His Ile Leu Val Val Ile Val

430 440 450 460 470 480
 CCACTGGAAAGGTGATGCCAACATTAACTTCGACAAATTCCGATTGGTTTCGAA
 ProLeuValGluGlyAspAlaGlnSerTyrAsnPheAspAsnSerAspLeuValPheGlu
 490 500 510 520 530 540
 TACTCTAATACTGACTTCTCTTGAAGTTATTAGATCATCTACTAAAGAAGTTTTATT
 TyrSerAsnThrAspPheSerPheGluValIleArgSerSerThrLysGluValLeuPhe
 550 560 570 580 590 600
 TCTACTAAAGGTAATCCATTGGTTTCAAAATCAATTCAATTCCGTCATTG
 SerThrLysGlyAsnProLeuValPheSerAsnGlnPheIleGlnPheAsnSerSerLeu
 610 620 630 640 650 660
 CCAAAGAACCATGTTATTACTGGTCTTGGTGAATCTTACGGTTAGTTAACGAAACCA
 ProLysAsnHisValIleThrGlyLeuGlyGluSerIleHisGlyLeuValAsnGluPro
 670 680 690 700 710 720
 GGTAGCGTTAAACATTATTGGCTTAATGATGGTGGTGAATCGATGGTAATTATTAT
 GlySerValLysThrLeuPheAlaAsnAspValGlyAspProIleAspGlyAsnIleTyr
 730 740 750 760 770 780
 GGTGGCATCCAGTTTATCTTGATCAAAGATATGACACTGAAACTACCCATGCTGGTTAT
 GlyValHisProValIleTyrAspThrGluThrThrHisAlaValIleTyr
 790 800 810 820 830 840
 TGGAGAACTCTGGTATTCAAGAAAGTATTAAATCGGGTGAAGGAATCTTACTGGAGAGCT
 TrpArgThrSerAlaIleGlnGluValIleGlyGluGluSerIleThrTrpArgAla

850 860 870 880 890 900
 CTT CAGGT ATT GATT TACT TCT TAG TGG CCT AC ACC AAAG ATGCC ATT CAA
 Leu Ser Gly Val Leu Asp Leu Tyr Phe Phe Ser Gly Pro Thr Pro Lys Asp Ala Leu Glu
 910 920 930 940 950 960
 CAG TAT GTCA AAAG AGATT TAC CAG CCT TCC AA ACC CATA CTG GCT CCG TT AGG TT ACC AT
 Glu Tyr Val Leu Glu Ile Glu Leu Pro Ala Phe Glu Pro Glu Pro Ile Phe Glu Ile Phe Glu
 970 980 990 1000 1010 1020
 CAAT GTAG ATGG GGT TAC GG ATAC TAT CGAA AAA ATT ATC TGA AGT GTG TGA AAA ACT TCA AG
 Glu Cys Arg Trp Glu Tyr Asp Thr Ile Glu Ile Glu Val Val Ile Glu Asn Phe Glu Asn Phe Glu
 1030 1040 1050 1060 1070 1080
 AA ATT TAA ATT CCA TT CATT AGAA AAC TAT CTGG TCA GAC ATT GATT ACAT GG ACT CT TATA AA
 Lys Phe Asn Ile Phe Leu Glu Thr Ile Trp Ser Asp Ile Asp Tyr Met Asp Ser Tyr Lys
 1090 1100 1110 1120 1130 1140
 GATT TCA CTT ATT GAT CC CACT A TAG AT GG AA ATT C GTAA ATT CCT TGA T GAG
 Asp Phe Thr Tyr Asp Pro His Arg Phe Pro Leu Asp Glu Ile Tyr Arg Gly Asp Phe Leu Asp Glu
 1150 1160 1170 1180 1190 1200
 TTG CAC AAA ATA ATT CAA CACT AT GTT CCT ATT TGG AT GCT ATT AC G TT CCA AAC
 Leu His Lys Asn Asn Glu Ile His Tyr Val Pro Ile Leu Asp Ala Ile Tyr Val Pro Asn
 1210 1220 1230 1240 1250 1260
 CCA AAC CAA ATT GCT AC GG ATA AAC GA A ATT CCA ACC TT CCA CT ATT GG TA AT GAA ACC GAT GTC
 Pro Asn Asn Ile Thr Asp Asn Glu Ile Tyr Glu Ile Pro Phe His Tyr Gly Asn Glu Thr Asp Val

1690 1700 1710 1720 1730 1740
 TATGCTATTACAAACATGCCAAGGTGACTCCGATCTTGTCTACTCATGCCAGTATGCCAAAT
 TyrAlaIleTyrAsnMetGlnGlyAspSerAlaThrHisAlaValSerProAsn

 1750 1760 1770 1780 1790 1800
 GCTACACATGCTGATGGTACAGTTGAATATGATATTCAAACTTCTTATGGTTACTTGC
 AlaThrHisAlaAspGlyThrValGluTyrAspIleHisAsnLeuTyrGlyTyrLeuGly

 1810 1820 1830 1840 1850 1860
 GAAAATGCTACTTTATGCCATTATGGAAATTCTAACAAAGGACCATTCATGATT
 GluAsnAlaThrThrHisAlaLysLysGluValPheProAsnLysArgProProMetIle

 1870 1880 1890 1900 1910 1920
 TCCAGATCAACCTTCCACGGGCTGGTAAATGGACCGGCCATTGGGGTGGTGACAACACT
 SerArgSerThrPheProArgAlaGlyLysTrpThrGlyHisTrpGlyLysAspAsnThr

 1930 1940 1950 1960 1970 1980
 GCTGATTGGCTTATGCTTACTTCCTCTCAAGGCATTCTCAATGGGTATTGGCTGGC
 AlaAspTrpAlaTyrPheSerSerProAlaPheSerSerMetGlyLysAlaGly

 1990 2000 2010 2020 2030 2040
 CTTCCATTCTTGGTGGCGATGTTGTTCAATGGTAATTCTGATTCTGAATTATGTT
 LeuProPhePheGlyAlaAspValCysGlyPheAsnGlyAlaSerAspSerGluLeuCys

 2050 2060 2070 2080 2090 2100
 TCAAGGATGGATGCCAATTAGGTTCCTTCTCCATTCTACABAAACCTATTAGGT
 SerArgTrpMetGlnLysGlySerPheProPheTyrArgAsnHisAsnTyrLeuGly

2530 2540 2550 2560 2570 2580
 ACTGTTGCTGAGTCAGAACAAATCCATTGGTTAATTGTCGCTTACCATGGCC
 ThrValAlaGluSerArgGlnAsnProPheGlyLeuIleValAlaLeuAspAspGly

 2590 2600 2610 2620 2630 2640
 AACAGCTCAAGGTABCTTACCTTGTGATAACATTTAGCTGACTCTTCAATTG
 LysAlaGlnGlySerLysSerTyrLeuAspAspGlyGluSerLeuSerLeu

 2650 2660 2670 2680 2690 2700
 TTGGTTCTCTCTGTTCTGATAACACATTACAGCATCTCCATCTGGTGAECTATAAA
 LeuValSerPheSerValSerAspAsnThrLeuSerAlaSerProSerGlyAspTyrLys

 2710 2720 2730 2740 2750 2760
 GCTGATCAACCTTTAGCTTAATGTTACCCATCTTAGGGGTGCCCCATAAACCAAAATCAGTT
 AlaAspGlnProLeuAlaAsnValThrIleLeuGlyValGlyHisAlaLysProLysSerVal

 2770 2780 2790 2800 2810 2820
 AAATTGAAACGCTTAATGTTGATTCACTTACAAAGAAATCAACCGTTTCTGGTTACTGGCC
 LysPheGluAsnAlaAsnValAspPheThrTyrLysSerThrValPheValThrGly

 2830 2840 2850 2860 2870 2880
 TTAGATAAAACCAAGGATGGCATTCTAAGGATTCAACCATTAACCTGGTAAATT
 LeuAspLysTyrThrLysAspGlyAlaPheSerLysAspPheThrIleThrTrp

 2890 2900 2910 2920 2930 2940
 TAACATCCACCTTAGTTCAATTCCATTCTTTCTTCCCGTGAATTCTGAATTGAAA

2950 2960 2970 2980 2990 3000
 TTATTTGAATGATAATCATTTAGTTCTTCAGCTTATGCTATGTTGATAAAATAGTTAA

 3010 3020 3030 3040 3050 3060
 ATGTTAAAGTTTATGTTATGTTGTTTATTGATGTTGATAAAATAGCAAA


 3070 3080 3090 3100 3110 3120
 TACATCGAAAATTGGATGAAATTGGCAGCTCATTTAGAAATGTTAGTCATTAGT

 3130 3140 3150 3160 3170 3180
 CACATTGGACCACTATAACAAACAAACTATTCCAAAGAAAAATATGTTAAGGATAAC

 3190 3200 3210 3220 3230 3240
 TAGATCATAAATTCTTATTGACTTTGTTTAAACAAATAGTTACATAAGGAATAATTCG

 3250 3260 3270 3280 3290 3300
 TTTACTACAAACCATTEGGTCTTGTAAAGCAGACGAGCCGATGTTGGGTTGCCG


 3310 3320
 CGCAATACTAGTTACAAAG



— M13
 □ α Amylase
 0.2 kb of the structural gene
 — α Amylase-Promoter
 E Eco RI
 Ps Pst I
 Bg Bgl II
 EV Eco RV

| | |
|----|----------|
| Aa | Aat II |
| A | Asp 718 |
| B | Bam H I |
| Sm | Sma I |
| S | Sal I |
| H | Hind III |
| Sc | Scal I |
| X | Xho I |

FIG. 3




□ Glucoamylase

— pMac5-8
Kramer et al. 1984

EV Eco RV
B Bam H I
Bg Bgl II
S Sal I
Ps Pst I

H Hind III
Xb Xba I
E Eco RI
Sm Sma I


FIG.4



| | | | |
|-----|------------------------------------------------|----|---------|
| ■■■ | TRP/ ARS | E | Eco R I |
| ■■■ | α Amylase-Promoter | B | Bam H I |
| □ | Glucoamylase structural gene | Bg | Bgl II |
| — | YRp7 Struhl et al.1979 | EV | Eco RV |
| ■■■ | α Amylase 0.4 kb of the structural gene | X | Xho I |
| | | S | Sal I |

FIG.5

Fig. 6a1






Fig.6 a 2






Fig.6b,2









Fig. 6c, 2

Fig. 6d,1






Fig.6d,2

Fig.7a






Fig.7b










Fig.8a,2

Fig. 8b1.










Fig.8c,2








Fig. 9 b,1




Fig.9b,2




Fig. 10,1





Fig.10,2





European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 89 10 7780

| DOCUMENTS CONSIDERED TO BE RELEVANT | | | CLASSIFICATION OF THE APPLICATION (Int. Cl.5) | | | | | | | | | | | | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|-----------------|----------------------------------|----------|-----------|------------|-----------------|-----------------------------|--|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|
| Category | Citation of document with indication, where appropriate, of relevant passages | Relevant to claim | | | | | | | | | | | | | |
| A,D | EP-A-0 260 404 (HEINEKEN TECHNISCH BEHEER B.V.) --- | 1 | C 12 N 1/19 C 12 P 21/02 C 12 N 15/81 // (C 12 N 1/19 C 12 R 1:645) | | | | | | | | | | | | |
| A,D | EP-A-0 257 115 (HEINEKEN TECHNISCH BEHEER B.V.) --- | 1 | | | | | | | | | | | | | |
| A | EP-A-0 256 421 (PHILLIPS PETROLEUM CO.) --- | | | | | | | | | | | | | | |
| A | SCIENCE, vol. 229, 20th September 1985, pages 1219-1224, Washington, DC, US; R.A. SMITH et al.: "Heterologous protein secretion from yeast" --- | | | | | | | | | | | | | | |
| A | CRC - CRITICAL REVIEWS IN BIOTECHNOLOGY, vol. 5, no. 2, 1987, pages 159-176, Boca Raton, Florida, US, W.M. INGLEDEW: "Schwanniomyces: a potential supereast?" ----- | | | | | | | | | | | | | | |
| | | | TECHNICAL FIELDS SEARCHED (Int. Cl.5) | | | | | | | | | | | | |
| | | | C 12 N C 12 P | | | | | | | | | | | | |
| <p>The present search report has been drawn up for all claims</p> <table border="1"> <tr> <td>Place of search</td> <td>Date of completion of the search</td> <td>Examiner</td> </tr> <tr> <td>THE HAGUE</td> <td>02-02-1990</td> <td>VAN PUTTEN A.J.</td> </tr> <tr> <td colspan="2">CATEGORY OF CITED DOCUMENTS</td> <td>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</td> </tr> <tr> <td colspan="2">X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</td> <td></td> </tr> </table> | | | | Place of search | Date of completion of the search | Examiner | THE HAGUE | 02-02-1990 | VAN PUTTEN A.J. | CATEGORY OF CITED DOCUMENTS | | T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document | X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document | | |
| Place of search | Date of completion of the search | Examiner | | | | | | | | | | | | | |
| THE HAGUE | 02-02-1990 | VAN PUTTEN A.J. | | | | | | | | | | | | | |
| CATEGORY OF CITED DOCUMENTS | | T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document | | | | | | | | | | | | | |
| X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document | | | | | | | | | | | | | | | |

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.